Your browser is no longer supported. Please, upgrade your browser.
Rhythm Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.29 Insider Own2.98% Shs Outstand50.25M Perf Week-15.21%
Market Cap381.50M Forward P/E- EPS next Y-3.57 Insider Trans0.00% Shs Float49.53M Perf Month-36.47%
Income-61.60M PEG- EPS next Q-0.91 Inst Own98.80% Short Float7.87% Perf Quarter-34.23%
Sales1.30M P/S293.46 EPS this Y21.40% Inst Trans0.01% Short Ratio11.17 Perf Half Y-63.54%
Book/sh6.41 P/B1.14 EPS next Y-109.80% ROA-18.20% Target Price30.14 Perf Year-81.51%
Cash/sh6.28 P/C1.16 EPS next 5Y16.10% ROE-20.20% 52W Range7.55 - 43.26 Perf YTD-26.85%
Dividend- P/FCF- EPS past 5Y-45.40% ROI- 52W High-83.13% Beta1.38
Dividend %- Quick Ratio14.30 Sales past 5Y- Gross Margin72.80% 52W Low-3.31% ATR0.77
Employees90 Current Ratio14.30 Sales Q/Q- Oper. Margin- RSI (14)29.12 Volatility9.87% 7.71%
OptionableYes Debt/Eq0.00 EPS Q/Q8.80% Profit Margin- Rel Volume0.98 Prev Close7.59
ShortableYes LT Debt/Eq0.00 EarningsNov 02 BMO Payout- Avg Volume348.86K Price7.30
Recom2.60 SMA20-25.54% SMA50-29.07% SMA200-51.90% Volume341,756 Change-3.82%
Dec-08-21Initiated Wells Fargo Overweight $30
Nov-19-21Downgrade Morgan Stanley Overweight → Equal-Weight $50 → $15
Sep-14-21Resumed Goldman Neutral $14
Aug-04-21Downgrade Ladenburg Thalmann Buy → Neutral
Aug-04-21Downgrade BofA Securities Neutral → Underperform $33 → $17
Nov-30-20Downgrade BofA Securities Buy → Neutral $27 → $33
Jan-08-20Initiated Goldman Sell $18
Jul-12-19Upgrade Stifel Hold → Buy $34
Jul-08-19Initiated Canaccord Genuity Buy $35
Mar-13-19Initiated Ladenburg Thalmann Buy $43
Sep-07-18Resumed Morgan Stanley Overweight
Jun-25-18Reiterated Needham Buy $36 → $42
Jun-15-18Reiterated Needham Buy $32 → $36
Oct-30-17Initiated Needham Buy $32
Oct-30-17Initiated BofA/Merrill Buy $30
Jan-13-22 09:15AM  
Dec-11-21 05:38AM  
Dec-10-21 09:10AM  
Dec-09-21 09:31AM  
Dec-06-21 08:00AM  
Nov-15-21 07:45AM  
Nov-09-21 04:01PM  
Nov-02-21 07:00AM  
Nov-01-21 04:01PM  
Oct-20-21 08:00AM  
Oct-14-21 04:01PM  
Oct-11-21 02:50PM  
Sep-22-21 10:30AM  
Sep-21-21 07:57PM  
Sep-20-21 07:30AM  
Sep-08-21 04:01PM  
Sep-02-21 04:01PM  
Aug-12-21 07:45AM  
Aug-05-21 12:00PM  
Aug-03-21 07:01AM  
Jul-29-21 08:00AM  
Jul-28-21 04:01PM  
Jul-27-21 08:00AM  
Jul-26-21 05:20PM  
Jul-23-21 10:15AM  
Jul-22-21 08:00AM  
Jul-12-21 09:41AM  
May-27-21 08:00AM  
May-21-21 08:39AM  
May-05-21 08:00AM  
May-03-21 10:55AM  
Apr-13-21 05:49AM  
Apr-09-21 02:16PM  
Apr-07-21 08:00AM  
Mar-20-21 11:30AM  
Mar-09-21 08:00AM  
Mar-01-21 08:00AM  
Feb-24-21 08:30AM  
Feb-12-21 04:12AM  
Feb-10-21 05:23PM  
Feb-04-21 09:49PM  
Feb-03-21 04:01PM  
Jan-26-21 07:00AM  
Jan-19-21 08:00AM  
Jan-05-21 08:17AM  
Dec-22-20 07:00AM  
Dec-11-20 08:15AM  
Dec-10-20 11:44AM  
Dec-02-20 12:56PM  
Nov-30-20 02:37PM  
Nov-29-20 04:59AM  
Nov-27-20 01:19PM  
Nov-04-20 04:30PM  
Nov-02-20 08:00AM  
Oct-30-20 07:30PM  
Oct-28-20 08:00AM  
Oct-20-20 02:10PM  
Oct-09-20 08:40AM  
Oct-05-20 10:15AM  
Sep-14-20 04:01PM  
Sep-09-20 08:00AM  
Sep-01-20 08:38AM  
Aug-06-20 08:00AM  
Aug-03-20 08:00AM  
Jul-27-20 08:00AM  
Jul-20-20 07:30AM  
Jul-16-20 08:00AM  
Jul-01-20 08:00AM  
Jun-26-20 11:20AM  
May-26-20 08:00AM  
May-13-20 09:00AM  
May-05-20 08:00AM  
May-04-20 08:00AM  
Apr-21-20 12:14PM  
Apr-07-20 08:00AM  
Mar-30-20 08:00AM  
Mar-18-20 08:00AM  
Mar-02-20 08:00AM  
Feb-25-20 08:00AM  
Jan-07-20 01:11PM  
Jan-06-20 04:15PM  
Dec-17-19 05:05PM  
Dec-05-19 08:00AM  
Nov-22-19 07:09AM  
Nov-13-19 08:01AM  
Nov-04-19 04:01PM  
Nov-01-19 08:31AM  
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alstrom syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Smith Hunter CChief Financial OfficerApr 21Option Exercise6.885,00034,40038,650Apr 23 06:08 AM
Meeker David PPresident and CEOMar 30Buy20.1710,000201,713111,335Mar 31 04:08 PM
Foley ToddDirectorMar 15Sale25.101,000,00025,100,000909,258Mar 16 05:13 PM